Inivata to Present at AACR Annual Meeting 2017

Inivata, a global clinical cancer genomics company employing a revolutionary approach to circulating tumor DNA (ctDNA) analysis to improve personalized healthcare in oncology, today announces the presentation of new data at the AACR Annual Meeting 2017 in Washington, USA.

The data, entitled “Comparison of enhanced Tagged-Amplicon Sequencing and digital PCR for circulating tumor DNA analysis in advanced breast cancer”, will be presented on Monday 3 April from 1:00pm – 5:00pm at the Convention Center. The poster will present the results of a new study showing ctDNA analysis using Inivata’s InVision^TM platform and Digital PCR (dPCR) have very a high concordance in mutation detection in patients with advanced breast cancer.

Clive Morris, Chief Medical Officer of Inivata, said:

“These results add to our growing body of evidence for the clinical utility of our InVision^TM platform across a number of cancer types. While we have recently announced the results of a first study of the use of a ctDNA liquid biopsy in guiding treatment decisions and delivering better patient outcomes in lung cancer patients, here we explore the utility of ctDNA in breast cancer. These data demonstrate that while our InVision platform has strong concordance with dPCR in breast cancer patients, it also yields more clinically useful biomarker information through a broad panel approach over individual mutational analysis.”